Detalhe da pesquisa
1.
SARS-CoV-2 DNA Vaccine INO-4800 Induces Durable Immune Responses Capable of Being Boosted in a Phase 1 Open-Label Trial.
J Infect Dis
; 225(11): 1923-1932, 2022 06 01.
Artigo
Inglês
| MEDLINE | ID: mdl-35079784
2.
CD8+ T Cells Impact Rising PSA in Biochemically Relapsed Cancer Patients Using Immunotherapy Targeting Tumor-Associated Antigens.
Mol Ther
; 28(5): 1238-1250, 2020 05 06.
Artigo
Inglês
| MEDLINE | ID: mdl-32208168
3.
Intradermal SynCon® Ebola GP DNA Vaccine Is Temperature Stable and Safely Demonstrates Cellular and Humoral Immunogenicity Advantages in Healthy Volunteers.
J Infect Dis
; 220(3): 400-410, 2019 07 02.
Artigo
Inglês
| MEDLINE | ID: mdl-30891607
4.
Phase 1 study of safety, tolerability and immunogenicity of the human telomerase (hTERT)-encoded DNA plasmids INO-1400 and INO-1401 with or without IL-12 DNA plasmid INO-9012 in adult patients with solid tumors.
J Immunother Cancer
; 9(7)2021 07.
Artigo
Inglês
| MEDLINE | ID: mdl-34230114
5.
INO-4800 DNA vaccine induces neutralizing antibodies and T cell activity against global SARS-CoV-2 variants.
NPJ Vaccines
; 6(1): 121, 2021 Oct 14.
Artigo
Inglês
| MEDLINE | ID: mdl-34650089
6.
Safety and immunogenicity of INO-4800 DNA vaccine against SARS-CoV-2: A preliminary report of an open-label, Phase 1 clinical trial.
EClinicalMedicine
; 31: 100689, 2021 Jan.
Artigo
Inglês
| MEDLINE | ID: mdl-33392485